유방암 환자의 선행항암화학요법 중 유방암의 진행 예측인자에 관한 연구

DC Field Value Language
dc.contributor.advisor한세환-
dc.contributor.authorJin, Ming-
dc.date.accessioned2019-10-21T07:28:24Z-
dc.date.available2019-10-21T07:28:24Z-
dc.date.issued2016-08-
dc.identifier.other23176-
dc.identifier.urihttps://dspace.ajou.ac.kr/handle/2018.oak/18899-
dc.description학위논문(석사)--아주대학교 일반대학원 :의학과,2016. 8-
dc.description.tableofcontentsⅠ. INTRODUCTION 1 Ⅱ. METHODS 2 A. Study population 2 B. Staging and Treatment 2 C. Assessment of tumor response 3 D. Statistical analysis 3 Ⅲ. RESULTS 4 A. Response to anthracycline-based regimen 4 B. Response to taxane-based regimen 5 C. Pathologic response after neoadjuvant chemotherapy 8 D. Predictive factors of no response to neoadjuvant chemotherapy 8 E. Clinical outcomes 10 Ⅳ. DISCUSSION 12 Ⅴ. CONCLUSION 16 REFERENCES 17-
dc.language.isoeng-
dc.publisherThe Graduate School, Ajou University-
dc.rights아주대학교 논문은 저작권에 의해 보호받습니다.-
dc.title유방암 환자의 선행항암화학요법 중 유방암의 진행 예측인자에 관한 연구-
dc.title.alternativePredictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer-
dc.typeThesis-
dc.contributor.affiliation아주대학교 일반대학원-
dc.contributor.alternativeNameJIN MING-
dc.contributor.department일반대학원 의학과-
dc.date.awarded2016. 8-
dc.description.degreeMaster-
dc.identifier.localId758806-
dc.identifier.urlhttp://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176-
dc.subject.keywordneoplasms-
dc.subject.keywordNeoadjuvant therapy-
dc.subject.keywordDisease Progression-
dc.description.alternativeAbstract- ABSTRACT - Predictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer Purpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC. Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy. Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival. Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.-
Appears in Collections:
Graduate School of Ajou University > Department of Medicine > 3. Theses(Master)
Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse